“英国巴菲特”特里·史密斯在年度股东会上，回答了8个最富争议的话题

Core Insights - The core message of the article emphasizes the investment philosophy of Terry Smith and Fundsmith, focusing on principles such as buying good companies, not overpaying, and maintaining a long-term perspective without frequent trading [1][4][7]. Investment Philosophy - Fundsmith's investment strategy is based on three key principles: 1. Buy good companies, defined by strong financial metrics such as high return on capital employed (ROCE) and gross margin [5][6]. 2. Don't overpay, with a focus on free cash flow yield as a measure of valuation [6][7]. 3. Do nothing, meaning that the best returns come from holding quality companies over time rather than frequent trading [7][8]. Market Trends and Insights - The discussion highlighted the impact of GLP-1 weight loss drugs, with the global market expected to grow from approximately $31.6 billion to between $100 billion and $350 billion in the coming years [8][9]. - The article also addressed the implications of potential tariff increases under a returning Trump administration, emphasizing that investment decisions should focus on the fundamental business operations rather than unpredictable political changes [10][11]. Active vs. Passive Management - Terry Smith argued that active management has a future, as it allows for selective investment in quality companies, contrasting with passive strategies that may lead to overvaluation of large-cap stocks [3][4]. - The article discussed the importance of understanding the underlying business quality and resilience in the face of market changes, rather than merely following market trends [10][11]. Controversial Holdings - Fundsmith's controversial holdings include Philip Morris, Novo Nordisk, and Unilever, each facing different market debates regarding ESG concerns, valuation, and management effectiveness [2][20][21]. - The article noted that Philip Morris has shifted significantly towards reduced-risk products, with a substantial portion of its revenue now coming from non-combustible products [20]. - Novo Nordisk's valuation concerns were addressed, with a focus on its strong financial metrics compared to competitors [21]. Management Incentives - The article highlighted the importance of management incentive structures, with Fundsmith often opposing poorly designed compensation plans that do not align with long-term shareholder value [15][16]. - Effective incentive mechanisms were illustrated through examples of companies that successfully align management goals with shareholder interests [16][19]. Dividend Strategy - Fundsmith's stance against investing solely for dividends was emphasized, advocating for a focus on companies that can reinvest profits effectively for long-term growth [17][19]. - The article provided examples of companies that have successfully increased dividends over time, reinforcing the idea that strong growth potential is more critical than immediate dividend yields [19].